{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202288","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.622006+00:00","generated_at":"2026-06-12T08:29:54.508047+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Wave Life Sciences Q2 net loss narrows to $21.1M; revenue jumps to $22.1M on GSK collaboration","bullets":["Net loss of $21.1M vs $41.3M YoY; revenue of $22.1M from GSK/Takeda collaborations vs $0.4M in Q2 2022.","Cash and equivalents $173.0M at June 30, 2023, up from $88.5M at Dec 2022; runway into 2025.","Imminent CTA submission for WVE-006 (AATD RNA editing candidate); first-in-human study expected 2H 2023.","DMD candidate WVE-N531 on track for potentially registrational Phase 2 dosing in 2H 2023; dystrophin data in 2024.","Discontinued WVE-004 for C9-ALS/FTD, but biomarker data validated PN chemistry; HD candidate WVE-003 multi-dose dosing underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202288","json":"https://secwatch.observer/filing/0001193125-23-202288.json","markdown":"https://secwatch.observer/filing/0001193125-23-202288.md","text":"https://secwatch.observer/filing/0001193125-23-202288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/0001193125-23-202288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/d584115d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:29:54.508047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8140e175597bfdfed1a13bf401150c1437399cde","claim":"Wave Life Sciences Ltd. reported the quarter ended June 30, 2023 results: revenue $22.1 million, net income a net loss of $21.1 million.","evidence_excerpt":"under the company’s collaboration with GSK, which became effective January 27, 2023. Revenue recognized under the GSK and Takeda collaborations in the second quarter of 2023 was $22.1 million. During the second quart","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523202288/0001193125-23-202288-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$22.1 million"},{"label":"Net income","value":"a net loss of $21.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}